GSE184653
PBMC Gene expression of participants in the kick and kill clinical trial BCN02
The BCN02 (NCT02616874)  was a pilot study to evaluate the kick and kill therapy on 15 early-treated individuals that were rolled-over from the BCN01 Study.  The participants in the study received two MVA.HIVconsv vaccination before and after the 3-cycle infusion of Romidepsin, an inhibitor of histone deacetylases that act as a latency reversing agent. Additionally, the inclusion of a monitored antiretroviral pause (MAP) allowed tthe identification of 8 individuals with an Early Rebound (pVL > 2,000 HIV RNA copies/mL, < 4 weeks of MAP initiation) and 4, with a Late Rebound (pVL > 2,000 HIV RNA copies/mL, > 4 weeks of MAP initiation).  In the present study we studied gene expression at 3 different timepoints: w0 (Bsl), w1 (Vacc),  w6 (Vacc+RMD) and applied pairwise comparisons. Overall design: PBMCs from the 15 individuals enrolled in BCN02 clinical trial were taken at 5 different timepoints: w0, w1, w6, MAP and w24.